Tweet
Share
E-mailCybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, accomplished a host of major milestones in 2021, proving it is on the right path to success. The company was awarded a notice of allowance by the U.S. Patent and Trademark Office for its CYB004 (deuterated psychedelic tryptamine) for the treatment of anxiety disorders and FDA approvals for its co-funded investigator-initiated phase 2 clinical trial. Cybin also confirmed a scientific advice meeting with the UK’s Medical and Healthcare Products Regulatory Agency regarding its lead candidate CYB003 for the treatment of major depressive disorder and alcohol use disorder and also announced positive CYB003 data. Other 2021 highlights included a grant for a psychedelic treatment clinic, securing a Schedule I manufacturing license from the U.S. DEA for its Boston-area research lab, receiving approval from the FDA for its IND application, and the completion of 74 in-vitro and in-vivo evaluations if its expanding portfolio of psychedelic compounds. The company also expanded its operations into Europe and was the first psychedelic company to list on the NYSE American market. Cybin CEO Doug Drysdale is quoted in a recent article as saying, “We believe 2022 will be a truly transformative year for Cybin.”
To view the full article, visit https://ibn.fm/9LSWq
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
